{"schema_version":"secwatch.filing_event.v1","accession":"0001650664-25-000020","form_type":"8-K","ticker":"EDIT","cik":"0001650664","company_name":"Editas Medicine, Inc.","filed_at":"2025-03-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.311025+00:00","generated_at":"2026-05-25T10:33:16.631946+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Editas posts Q4 net loss $45.4M ($0.55/sh); ends reni-cel, cuts 65% staff","bullets":["Q4 2024 net loss $45.4M vs $18.9M in Q4 2023; full-year net loss $237.1M vs $153.2M.","Cash $269.9M; operational runway into Q2 2027 includes $45-55M in restructuring costs.","Ended reni-cel development due to failed partnership search; workforce reduced ~65%.","On track to declare in vivo HSC and liver development candidates via gene upregulation mid-2025.","No future quarterly earnings conference calls."],"urls":{"canonical":"https://secwatch.observer/filing/0001650664-25-000020","json":"https://secwatch.observer/filing/0001650664-25-000020.json","markdown":"https://secwatch.observer/filing/0001650664-25-000020.md","text":"https://secwatch.observer/filing/0001650664-25-000020.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1650664/000165066425000020/0001650664-25-000020-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1650664/000165066425000020/edit-20250305.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-25T10:33:16.631946+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}